Alyssa Wohlfahrt1, Clifton O Bingham2, Wendy Marder3, Kristine Phillips4, Marcy B Bolster5, Larry W Moreland6, Zhi Zhang1, Tuhina Neogi7, Yvonne C Lee1. 1. Brigham and Women's Hospital, Boston, Massachusetts. 2. Johns Hopkins University, Baltimore, Maryland. 3. University of Michigan Medical School, Ann Arbor. 4. Vanderbilt University, Nashville, Tennessee. 5. Massachusetts General Hospital, Boston, Massachusetts. 6. University of Pittsburgh, Pittsburgh, Pennsylvania. 7. Boston University School of Medicine, Boston, Massachusetts.
Abstract
OBJECTIVE: The Patient-Reported Outcomes Measurement Information System (PROMIS) is a calibrated item bank used to assess patient-reported outcomes across multiple domains. The purpose of this study was to describe the performance of selected PROMIS measures in patients with rheumatoid arthritis (RA) with active disease who were initiating a disease-modifying antirheumatic drug (DMARD). METHODS: Participants in an ongoing prospective observational study completed 8 PROMIS measures before and after DMARD initiation. Linear regression models were performed to identify cross-sectional associations between baseline PROMIS measures and disease activity, measured using the Clinical Disease Activity Index (CDAI). Paired t-tests were performed to evaluate responsiveness after 12 weeks of DMARD treatment. Associations between changes in PROMIS measures and changes in the CDAI score were assessed using linear regression. RESULTS: Among the 156 participants who completed the first study visit, the mean ± SD baseline CDAI score was 25.5 ± 14.0. Baseline scores for PROMIS measures of physical health, pain, and sleep were associated with the baseline CDAI score (P ≤ 0.05). Among the 106 participants with 12-week data, all PROMIS scores improved after DMARD initiation (P ≤ 0.05). With the exception of depression, changes in all assessed PROMIS measures were correlated with changes in the CDAI score (standardized βs from |0.23| to |0.38|). CONCLUSION: These data provide support for the utility of PROMIS measures for the assessment of physical and mental health in individuals with active RA. All PROMIS measures improved significantly after DMARD initiation, with the magnitudes of association between changes in PROMIS measures and changes in the CDAI score in the low-to-moderate range.
OBJECTIVE: The Patient-Reported Outcomes Measurement Information System (PROMIS) is a calibrated item bank used to assess patient-reported outcomes across multiple domains. The purpose of this study was to describe the performance of selected PROMIS measures in patients with rheumatoid arthritis (RA) with active disease who were initiating a disease-modifying antirheumatic drug (DMARD). METHODS:Participants in an ongoing prospective observational study completed 8 PROMIS measures before and after DMARD initiation. Linear regression models were performed to identify cross-sectional associations between baseline PROMIS measures and disease activity, measured using the Clinical Disease Activity Index (CDAI). Paired t-tests were performed to evaluate responsiveness after 12 weeks of DMARD treatment. Associations between changes in PROMIS measures and changes in the CDAI score were assessed using linear regression. RESULTS: Among the 156 participants who completed the first study visit, the mean ± SD baseline CDAI score was 25.5 ± 14.0. Baseline scores for PROMIS measures of physical health, pain, and sleep were associated with the baseline CDAI score (P ≤ 0.05). Among the 106 participants with 12-week data, all PROMIS scores improved after DMARD initiation (P ≤ 0.05). With the exception of depression, changes in all assessed PROMIS measures were correlated with changes in the CDAI score (standardized βs from |0.23| to |0.38|). CONCLUSION: These data provide support for the utility of PROMIS measures for the assessment of physical and mental health in individuals with active RA. All PROMIS measures improved significantly after DMARD initiation, with the magnitudes of association between changes in PROMIS measures and changes in the CDAI score in the low-to-moderate range.
Authors: Joshua F Baker; Philip G Conaghan; Paul Emery; Daniel G Baker; Mikkel Ostergaard Journal: Ann Rheum Dis Date: 2016-07-18 Impact factor: 19.103
Authors: Frederick Wolfe; Daniel J Clauw; Mary-Ann Fitzcharles; Don L Goldenberg; Winfried Häuser; Robert S Katz; Philip Mease; Anthony S Russell; I Jon Russell; John B Winfield Journal: J Rheumatol Date: 2011-02-01 Impact factor: 4.666
Authors: Helga Radner; Kazuki Yoshida; Sara Tedeschi; Paul Studenic; Michelle Frits; Christine Iannaccone; Nancy A Shadick; Michael Weinblatt; Daniel Aletaha; Josef S Smolen; Daniel H Solomon Journal: Arthritis Rheumatol Date: 2017-04 Impact factor: 10.995
Authors: Dagmar Amtmann; Karon F Cook; Mark P Jensen; Wen-Hung Chen; Seung Choi; Dennis Revicki; David Cella; Nan Rothrock; Francis Keefe; Leigh Callahan; Jin-Shei Lai Journal: Pain Date: 2010-07 Impact factor: 6.961
Authors: Daniel Aletaha; Valerie P K Nell; Tanja Stamm; Martin Uffmann; Stephan Pflugbeil; Klaus Machold; Josef S Smolen Journal: Arthritis Res Ther Date: 2005-04-07 Impact factor: 5.156
Authors: Vibeke Strand; Joel Kremer; Gene Wallenstein; Keith S Kanik; Carol Connell; David Gruben; Samuel H Zwillich; Roy Fleischmann Journal: Arthritis Res Ther Date: 2015-11-04 Impact factor: 5.156
Authors: Karen E Schifferdecker; Rebecca L Butcher; Erin Knight; Emily Creek; M Suzanne Schrandt; Laura Marrow; Marie Jaffe; Arlene Vinci; Guy Eakin Journal: ACR Open Rheumatol Date: 2020-11-25
Authors: Noelle E Carlozzi; Nicholas R Boileau; Matthew W Roché; Rebecca E Ready; Joel S Perlmutter; Kelvin L Chou; Stacey K Barton; Michael K McCormack; Julie C Stout; David Cella; Jennifer A Miner; Jane S Paulsen Journal: Qual Life Res Date: 2020-08-19 Impact factor: 4.147
Authors: Patricia Katz; Sofia Pedro; Evo Alemao; Jinoos Yazdany; Maria Dall'Era; Laura Trupin; Stephanie Rush; Kaleb Michaud Journal: ACR Open Rheumatol Date: 2019-12-04